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Clinicians often diagnose tumors based
on differences in tissue rigidity sensed by
palpation, and pathologists have long
known that cancer involves distinct
changes in the extracellular matrix (ECM)
that normally holds together cells within
distinct tissue patterns. Although this
matrix was initially viewed as a host barri-
er to tumor invasion, past studies have
suggested that changes of ECM structure
or mechanics, such as whether the matrix
is stiff enough to resist cell traction forces,
might actively contribute to
tumor formation (Ingber et al.,
1981). Alterations of mechani-
cal properties can, in fact,
influence tumor development,
as illustrated by experiments
that show that a rigid piece of
metal or plastic can trigger
cancer formation when
implanted in the body, where-
as tumors do not form when
the same material is intro-
duced as a powder (Bischoff
and Bryson, 1964). Normal
cells also need to attach to a
rigid matrix and physically
stretch to proliferate (Folkman
and Moscona, 1978), where-
as malignant cells lose 
this “shape dependence”
(Wittelsberger et al., 1981).
But how can the mechanics of
a material alter cell growth,
destroy tissue architecture,
and induce cancer formation?
Only now, as a result of
the vast amount of accumu-
lating knowledge about how
cells sense mechanical sig-
nals and convert them into
changes in cellular biochem-
istry, are we in a position to
unite cellular mechanotrans-
duction with oncogenic sig-
naling. Integrins have been
shown to modulate signaling by the EGF
receptor (EGFR), and to control the dif-
ferentiation and transformation of mam-
mary epithelial cells cultured on ECM
gels, but not on rigid planar substrates
(Wang et al., 1998). These transmem-
brane ECM receptors also act as
mechanoreceptors (Wang et al., 1993)
and mediate mechanotransduction by
transferring forces to specialized anchor-
ing structures, known as focal adhe-
sions, that both link integrins to the
cytoskeleton and orient much of the
cell’s signaling machinery (Bershadsky
et al., 2003). However, this is not a one-
way process. Cell traction forces gener-
ated in the actin cytoskeleton are exerted
on these same sites, and thus integrins
and focal adhesions are maintained in a
state of isometric tension. External
stresses also can feed back to increase
tension generation by activating the
small G protein Rho and its target Rho-
associated kinase (ROCK), which con-
trols myosin light chain phosphorylation.
Rho is mitogenic and can stimulate cell
cycle progression in the absence of cell
spreading (Roovers and Assoian,
2003). Thus, because changes of ECM
stiffness alter the cellular force 
balance, a mechanics-based positive
feedback control loop exists that can
impact cell proliferation.
In this issue of Cancer
Cell, Paszek et al. (2005)
explore the role of bi-
directional force transfer
across integrins in the con-
text of differentiation and
tumor formation. Using an
electromechanical indentor
to directly measure tissue
mechanics, they found that
explanted mouse mammary
tumors are stiffer than healthy
mammary gland. And, they
showed that undifferentiated
EGFR-transformed mamma-
ry tumor cells that display ele-
vated Erk activity also exhibit
higher Rho activity. They then
cultured normal mammary
epithelial cells on ECM gels
that varied in mechanical
compliance over the range
displayed by the normal and
cancer tissues they mea-
sured in vivo. Not only did the
stiff (force-resisting) ECM
gels promote expression of
the undifferentiated malig-
nant phenotype, but Rho
activity was also higher in
these cells. When constitu-
tively active RhoV14 was
overexpressed in normal
mammary cells adherent to a
soft matrix, they acquired the malignant
properties of the cells on the rigid gels:
they generated more force, disrupted
cell-cell junctions, spread, increased
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Oncologists often diagnose cancer based on a change of tissue stiffness sensed by palpation, yet cancer researchers gen-
erally focus on biochemical signaling mechanisms.Tumors are more rigid because they have a stiffer extracellular matrix.
A new study shows that this alteration of matrix mechanics activates integrins, which not only promotes mitogenic signal-
ing through Erk but also cell contractility through Rho, which can further increase matrix stiffness.This establishes a pos-
itive feedback loop that switches on the malignant phenotype in mammary epithelial cells. This mechanical “autocrine
loop” brings solid-state mechanotransduction on a par with oncogenic signaling pathways in malignant transformation.
Figure 1. A mechanical autocrine loop that may contribute to cancer
development
Increases of rigidity in the matrix that better resist cell tensional forces
activate integrins, promote focal adhesion assembly, and stimulate
the Rho/ROCK pathway which enhances cell contractility, thereby
further increasing matrix stiffness. Because of the crosstalk between
the integrin/Rho pathway and the canonical growth factor recep-
tor/Erk mitogenic signaling cascade, this self-sustaining positive feed-
back loop may stabilize the undifferentiated proliferative phenotype
of mammary epithelial cancer cells and lead to neoplastic disorgani-
zation of tissue architecture.
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proliferation, and lost acinar organiza-
tion. The dedifferentiated phenotype was
reversed by blocking tension generation
through pharmacological inhibition of
ROCK or myosin II, suggesting that the
transforming effect was not due to
pleiotropic biochemical Rho signaling,
but instead was specifically caused by
Rho-dependent tension. Interestingly,
the malignant phenotype of RhoV14
expressing cells was also normalized by
inhibition of Erk, which similarly reduced
force generation, pointing to the inter-
twining between the mitogenic EGFR/Erk
and mechanotransducing Rho/ROCK
pathways. Stress-induced aggregation of
integrins and subsequent focal adhesion
formation appeared to mediate all these
effects, as suggested by studies in which
cells were transfected with a mutated
form of β1 integrin which spontaneously
self-associates in the cell membrane;
these cells acted as if they were cultured
on rigid substrates, even when plated on
highly flexible ECM gels.
The ability of ECM mechanics and
cell tension to contribute to cancer for-
mation is intriguing. Increased stiffness
of the ECM as observed in tumors in vivo
may promote integrin clustering, Erk
activation, and Rho-mediated contractili-
ty. A rise of cell tension will further
increase ECM stiffness by tensing or
realigning ECM components, thereby
creating a deadly, self-sustaining posi-
tive feedback loop. Because Rho
crosstalks with the mitogenic pathways,
this self-maintained tensed state will sta-
bilize the proliferative phenotype as a
discrete behavioral program. This is the
solid-state version of an autostimulatory
loop known for soluble signals (Figure 1),
such as the autocrine secretion of
growth factors by tumor cells. A physical
cue devoid of chemical specificity may
therefore switch cells between entirely
different phenotypes, even between nor-
mal and cancerous states, perhaps by
initiating a cascade of multiple switches
that simultaneously trigger the leap from
one self-stabilizing “attractor” state to
another within the genome-wide cell reg-
ulatory network (Huang et al., 2005).
This mechanism also may explain why
continued culturing of normal cells for
many passages on rigid plastic dishes
often leads to spontaneous transforma-
tion in vitro.
Thus, cancer can no longer be
viewed solely as a result of dysregulation
of intracellular signaling pathways. This
regulatory activity of ECM mechanics
puts cell fate regulation and its patholog-
ical derailment that leads to neoplasia
back into the context of solid-state tissue
properties. Increased understanding of
the molecular basis of mechanotrans-
duction may lead to identification of an
entirely new class of molecular targets
for anticancer therapy.
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